Parameter Set Neuroleptics 1/EXTENDED - LC-MS/MS

Order No.: 92912/XT/RUO
Parameters:
9-OH-Risperidone, Aripiprazole, Clozapine, Haloperidol, N-Desmethylclozapine, N-Desmethylolanzapine, Olanzapine, Quetiapine, Risperidone

Encompasses 11 analytes
3PLUS1® Multilevel Calibrator Set available
Part of the modular system MassTox® Series A

 

Aripiprazole

Dehydroaripiprazole

Clozapine

N-Desmethylclozapine

Haloperidol

Olanzapine

N-Desmethylolanzapine

Quetiapine

Norquetiapine

Risperidone

9-OH-Risperidone

Clinical relevance

This parameter set allows the quantitative determination of aripiprazole, dehydroaripiprazole, clozapine, N-desmethylclozapine, haloperidol, olanzapine, N-desmethylolanzapine, quetiapine, norquetiapine, risperidone and 9-OH-risperidone in human serum or plasma samples via liquid chromatography mass spectrometry (LC-MS/MS).

 

MassTox® Series A

The MassTox® Series A is a modular system that enables the determination of all analytes without changing column or mobile phases, thereby minimising the workload in the laboratory.
It consists of 3 parts:
• MassTox® Basic Kit A
• Specific MassTox® Parameter Set
• Analytical column MassTox® TDM MasterColumn® A

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix.
  • Add 800 μl Internal Standard Mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl research sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 3 min
Injection Volume 0.2 – 50 µl
Gradient

0.00 - 0.20 min    20 % Mobile Phase 2
0.21 - 0.70 min    50 % Mobile Phase 2
0.71 - 2.30 min    70 % Mobile Phase 2
2.31 - 3.00 min    20 % Mobile Phase 2

Ionisation ESI
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters 9-OH-Risperidone, Aripiprazole, Clozapine, Haloperidol, N-Desmethylclozapine, N-Desmethylolanzapine, Olanzapine, Quetiapine, Risperidone
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:

Aripiprazole

Dehydroaripiprazole

Clozapine

N-Desmethylclozapine

Haloperidol

Olanzapine

N-Desmethylolanzapine

Quetiapine

Norquetiapine

Risperidone

9-OH-Risperidone

Clinical relevance

This parameter set allows the quantitative determination of aripiprazole, dehydroaripiprazole, clozapine, N-desmethylclozapine, haloperidol, olanzapine, N-desmethylolanzapine, quetiapine, norquetiapine, risperidone and 9-OH-risperidone in human serum or plasma samples via liquid chromatography mass spectrometry (LC-MS/MS).

 

MassTox® Series A

The MassTox® Series A is a modular system that enables the determination of all analytes without changing column or mobile phases, thereby minimising the workload in the laboratory.
It consists of 3 parts:
• MassTox® Basic Kit A
• Specific MassTox® Parameter Set
• Analytical column MassTox® TDM MasterColumn® A

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Specimen Serum/Plasma
Sample Preparation
  • Reconstitute the Internal Standard Mix.
  • Add 800 μl Internal Standard Mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl research sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 3 min
Injection Volume 0.2 – 50 µl
Gradient

0.00 - 0.20 min    20 % Mobile Phase 2
0.21 - 0.70 min    50 % Mobile Phase 2
0.71 - 2.30 min    70 % Mobile Phase 2
2.31 - 3.00 min    20 % Mobile Phase 2

Ionisation ESI
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters 9-OH-Risperidone, Aripiprazole, Clozapine, Haloperidol, N-Desmethylclozapine, N-Desmethylolanzapine, Olanzapine, Quetiapine, Risperidone
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method: